论文部分内容阅读
先灵葆雅(Schering-Plough)公司公布代号为SPRINT-1的丙型肝炎病毒(HCV)NS3蛋白酶抑制剂boceprevir(SCH-503034)的研究结果。SPRINT-1是在对peginterferon alfa-2b(PegIntron~(?))和利巴韦林(Copegus~(?))治疗无应答且从未接受过boceprevir治疗的HCV基因型1患者中进行的一项为期
Schering-Plow Company announces the results of a study of boceprevir (SCH-503034), a hepatitis C virus (HCV) NS3 protease inhibitor, codenamed SPRINT-1. SPRINT-1 is one of HCV genotype 1 patients who did not respond to peginterferon alfa-2b (PegIntron®) and ribavirin (Copegus ®) and never received boceprevir Period